I mentioned SAMR because there is a similar distinction between facility approval and product approval, which some may already be familiar with.
Also, the fact that BUB have failed to achieve SAMR product approval perhaps explains why they have been more proactive in regards to the USA market. I don't follow BUB that closely and I'm not sure if they have even applied for it. If you are classing me as a rusted on A2M holder, OK, but I've been critical of their USA strategy for years, and equally impressed by BUB's initiative on that front, so I am not really sure what your beef is.
A2M Price at posting:
$4.75 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)